New strategies for the treatment of pulmonary hypertension in sickle cell disease : the rationale for arginine therapy.
about
Nitric oxide and cardiovascular effects: new insights in the role of nitric oxide for the management of osteoarthritisDevelopmental changes in arginase expression and activity in the lungNewer aspects of the pathophysiology of sickle cell disease vaso-occlusion.Nitric oxide and arginine dysregulation: a novel pathway to pulmonary hypertension in hemolytic disordersErythrocyte glutamine depletion, altered redox environment, and pulmonary hypertension in sickle cell disease.The genomics of new drugs in sickle cell disease.Arginase and vascular aging.C-reactive protein and interleukin-6 are decreased in transgenic sickle cell mice fed a high protein diet.Pulmonary hypertension associated with sickle cell disease: pathophysiology and rationale for treatment.An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease.Therapeutic approaches to limit hemolysis-driven endothelial dysfunction: scavenging free heme to preserve vasculature homeostasis.Evolution of sickle cell disease from a life-threatening disease of children to a chronic disease of adults: The last 40 years.Nitric oxide metabolites and arginase I levels in β-thalassemic patients: an Egyptian study.Acquired Amino Acid Deficiencies: A Focus on Arginine and Glutamine.Arginase and arginine dysregulation in asthma.Nitric Oxide-Independent Soluble Guanylate Cyclase Activation Improves Vascular Function and Cardiac Remodeling in Sickle Cell Disease.New role for L-arginine in regulation of inducible nitric-oxide-synthase-derived superoxide anion production in raw 264.7 macrophages.
P2860
Q21195404-8E9C6078-5BFF-4F38-B9D7-D1ACF9C58344Q28579809-1CC61349-728B-4D05-A2D6-8542D4117554Q34941213-03150C98-476A-4A91-BEAA-FEBBA52ACAECQ35590733-82616BCA-F807-4177-A3E0-B5326429A382Q36384658-0780166B-A6FE-4D22-9E92-1AC3E6D1E625Q36596719-70CCD947-C875-4512-A98B-601557ABB733Q36977086-D897E168-1C97-4C4D-AB2A-6EF9979A5C2DQ37128824-C3ADE681-DD4A-40C1-9AA0-C8A4C844A83FQ37159329-4E15CBE2-9C9C-4096-8235-485CB6EDCBB8Q37698249-5E509363-C5FC-4B5A-B297-170404A031B4Q38115527-A465E8BA-2A3B-430D-A8F1-410215938205Q38627797-8064708A-34FE-48F0-A99C-C4AECEAE09AFQ38987725-7A33DAAC-09F5-4FB2-984E-21E86AEB38A6Q39226887-71413660-498D-47EE-B348-CA67C94B4B7BQ41831572-4A07D15D-22C3-4259-91BD-FFC40B16236BQ52738823-03B67C07-000A-4867-B0D8-027A75DB36AFQ54344856-047BF6F7-2E51-4FDA-B2DA-E585D9C95BBB
P2860
New strategies for the treatment of pulmonary hypertension in sickle cell disease : the rationale for arginine therapy.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
New strategies for the treatme ...... ationale for arginine therapy.
@ast
New strategies for the treatme ...... ationale for arginine therapy.
@en
New strategies for the treatme ...... ationale for arginine therapy.
@nl
type
label
New strategies for the treatme ...... ationale for arginine therapy.
@ast
New strategies for the treatme ...... ationale for arginine therapy.
@en
New strategies for the treatme ...... ationale for arginine therapy.
@nl
prefLabel
New strategies for the treatme ...... ationale for arginine therapy.
@ast
New strategies for the treatme ...... ationale for arginine therapy.
@en
New strategies for the treatme ...... ationale for arginine therapy.
@nl
P2860
P1476
New strategies for the treatme ...... ationale for arginine therapy.
@en
P2093
Claudia R Morris
P2860
P356
10.2165/00151829-200605010-00003
P577
2006-01-01T00:00:00Z
P5875
P6179
1023060592